Bioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.
Bioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, Uttar Pradesh, India; Jawahar Lal Nehru University, New Delhi 110067, India.
Biochem Pharmacol. 2021 Jul;189:114409. doi: 10.1016/j.bcp.2021.114409. Epub 2021 Jan 8.
MicroRNAs (miRNAs) are non-coding, conserved, single-stranded nucleotide sequences involved in physiological and developmental processes. Recent evidence suggests an association between miRNAs' deregulation with initiation, promotion, progression, and drug resistance in cancer cells. Besides, miRNAs are known to regulate the epithelial-mesenchymal transition, angiogenesis, autophagy, and senescence in different cancer types. Previous reports proposed that apart from the antioxidant potential, flavonoids play an essential role in miRNAs modulation associated with changes in cancer-related proteins, tumor suppressor genes, and oncogenes. Thus, flavonoids can suppress proliferation, help in the development of drug sensitivity, suppress metastasis and angiogenesis by modulating miRNAs expression. In the present review, we summarize the role of miRNAs in cancer, drug resistance, and the chemopreventive potential of flavonoids mediated by miRNAs. The potential of flavonoids to modulate miRNAs expression in different cancer types demonstrate their selectivity and importance as regulators of carcinogenesis. Flavonoids as chemopreventive agents targeting miRNAs are extensively studied in vitro, in vivo, and pre-clinical studies, but their efficiency in targeting miRNAs in clinical studies is less investigated. The evidence presented in this review highlights the potential of flavonoids in cancer prevention/treatment by regulating miRNAs, although further investigations are required to validate and establish their clinical usefulness.
微小 RNA(miRNA)是参与生理和发育过程的非编码、保守、单链核苷酸序列。最近的证据表明,miRNA 的失调与癌细胞的起始、促进、进展和耐药性有关。此外,miRNA 已知可调节不同癌症类型中的上皮-间充质转化、血管生成、自噬和衰老。先前的报告提出,除了抗氧化潜力外,类黄酮在 miRNA 调节中起着重要作用,这种调节与癌症相关蛋白、肿瘤抑制基因和癌基因的变化有关。因此,类黄酮可以通过调节 miRNA 的表达来抑制增殖、帮助产生药物敏感性、抑制转移和血管生成。在本综述中,我们总结了 miRNA 在癌症、耐药性以及 miRNA 介导的类黄酮的化学预防潜力中的作用。类黄酮作为 miRNA 的调节剂在不同癌症类型中的潜在作用表明了它们作为致癌作用调节剂的选择性和重要性。类黄酮作为针对 miRNA 的化学预防剂已在体外、体内和临床前研究中进行了广泛研究,但它们在临床研究中针对 miRNA 的效率研究较少。本综述中提出的证据强调了类黄酮通过调节 miRNA 来预防/治疗癌症的潜力,尽管需要进一步的研究来验证和确立其临床用途。